Response to rituximab in B-CLL patients is adversely impacted by frequency of IL-10 competent B cells and FcγRIIIa polymorphism. A study of FCGCLL/WM and GOELAMS groups
Domains
Life Sciences [q-bio]
Fichier principal
Response to rituximab in B-CLL patients is adversely impacted by frequency of IL-10.pdf (380.36 Ko)
Télécharger le fichier
Origin : Publisher files allowed on an open archive
Loading...